A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol.

Fraser IS, Shearman RP, Jansen RP, Sutherland PD

The Australian & New Zealand journal of obstetrics & gynaecology1 May 1991Cited by 27 (Europe PMC)

PMID1834049DOI10.1111/j.1479-828x.1991.tb01807.xPepBankPUB-01834049

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with endometriosis, nafarelin and danazol produced similar reductions in American Fertility Society scores.
In plain wordsIn patients with endometriosis, nafarelin and danazol reduced disease scores similarly.
Peptide
Nafarelin
Outcome
Direction not reportedAmerican Fertility Society score comparison
Study
n = 49
Comparator
Danazol
Outcome group
Organ injury · Reproductive and sexual health
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Both drugs produced a highly significant and similar reduction (of 60 to 70%) in objective American Fertility Society scoring, even in severe disease.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized and double-blind trial was carried out comparing intranasal nafarelin acetate (400 micrograms daily) and oral danazol (600 mg daily), given over 6 months, in the treatment of 49 patients with laparoscopically proven endometriosis.
Report a problemFND-0183404902
02HumanRandomized controlled trialMechanism
In patients with endometriosis, nafarelin and danazol suppressed oestradiol to a similar extent.
In plain wordsIn patients with endometriosis, nafarelin and danazol suppressed oestradiol similarly.
Peptide
Nafarelin
Outcome
Direction not reportedOestradiol suppression
Study
n = 49
Comparator
Danazol
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Both drugs suppressed oestradiol levels to a similar extent, although nafarelin caused a substantial rise in the first 2 weeks after the initiation of therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized and double-blind trial was carried out comparing intranasal nafarelin acetate (400 micrograms daily) and oral danazol (600 mg daily), given over 6 months, in the treatment of 49 patients with laparoscopically proven endometriosis.
Report a problemFND-0183404904
03HumanRandomized controlled trialSafety outcome
In patients with endometriosis, nafarelin and danazol had similar side-effect rates but different patterns.
In plain wordsIn patients with endometriosis, nafarelin and danazol had similar rates of side effects.
Peptide
Nafarelin
Outcome
Direction not reportedSide-effect rate
Study
n = 49
Comparator
Danazol
Outcome group
Adverse events · Whole body
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Side-effects were reported at a similar rate with both drugs, but the pattern was different.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized and double-blind trial was carried out comparing intranasal nafarelin acetate (400 micrograms daily) and oral danazol (600 mg daily), given over 6 months, in the treatment of 49 patients with laparoscopically proven endometriosis.
Report a problemFND-0183404911
04HumanRandomized controlled trialMechanism
In patients with endometriosis, nafarelin substantially suppressed LH, whereas LH increased slightly during danazol treatment.
In plain wordsIn patients with endometriosis, LH decreased with nafarelin but increased slightly with danazol.
Peptide
Nafarelin
Outcome
DecreaseLH compared with danazol
Study
n = 49
Comparator
Danazol
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Nafarelin suppressed LH substantially and FSH, testosterone and prolactin to a small degree, whereas FSH and LH increased slightly during danazol.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized and double-blind trial was carried out comparing intranasal nafarelin acetate (400 micrograms daily) and oral danazol (600 mg daily), given over 6 months, in the treatment of 49 patients with laparoscopically proven endometriosis.
Report a problemFND-0183404914
05HumanRandomized controlled trialMechanism
In patients with endometriosis, nafarelin slightly suppressed FSH, whereas FSH increased slightly during danazol treatment.
In plain wordsIn patients with endometriosis, FSH decreased slightly with nafarelin but increased slightly with danazol.
Peptide
Nafarelin
Outcome
DecreaseFSH compared with danazol
Study
n = 49
Comparator
Danazol
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Nafarelin suppressed LH substantially and FSH, testosterone and prolactin to a small degree, whereas FSH and LH increased slightly during danazol.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized and double-blind trial was carried out comparing intranasal nafarelin acetate (400 micrograms daily) and oral danazol (600 mg daily), given over 6 months, in the treatment of 49 patients with laparoscopically proven endometriosis.
Report a problemFND-0183404915
06HumanRandomized controlled trialEfficacy outcome
Pregnancies occurred in 12 of 22 infertile women after nafarelin and 6 of 14 after danazol during 12 months after treatment.
In plain wordsAmong infertile women, pregnancies occurred in 12 of 22 after nafarelin and 6 of 14 after danazol.
Peptide
Nafarelin
Outcome
IncreasePregnancy after treatment
Study
n = 36
Comparator
Danazol
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Measurements
Pregnancies
12 women
nafarelin
Women
22 women
nafarelin
Pregnancies
6 women
danazol
Women
14 women
danazol
Source sentences
Summary
Pregnancies occurred in 12 of 22 infertile women in the 12 months following nafarelin, and in 6 of 14 in the danazol group.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized and double-blind trial was carried out comparing intranasal nafarelin acetate (400 micrograms daily) and oral danazol (600 mg daily), given over 6 months, in the treatment of 49 patients with laparoscopically proven endometriosis.
Report a problemFND-0183404910
07HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, nafarelin reduced objective American Fertility Society scores by 60 to 70% from baseline.
In plain wordsIn patients with endometriosis, nafarelin reduced disease scores from baseline.
Peptide
Nafarelin
Outcome
DecreaseAmerican Fertility Society score
Study
n: not reported in source
Outcome group
Organ injury · Reproductive and sexual health
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Measurements
Score reduction
60 to 70%
nafarelin
Source sentences
Summary
Both drugs produced a highly significant and similar reduction (of 60 to 70%) in objective American Fertility Society scoring, even in severe disease.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized and double-blind trial was carried out comparing intranasal nafarelin acetate (400 micrograms daily) and oral danazol (600 mg daily), given over 6 months, in the treatment of 49 patients with laparoscopically proven endometriosis.
Report a problemFND-0183404901
08HumanNon-randomized trialEfficacy outcome
In this nafarelin versus danazol trial in patients with endometriosis, no effect was seen on adhesions.
In plain wordsIn a trial of nafarelin versus danazol in endometriosis, no effect was seen on adhesions.
Peptide
Nafarelin
Outcome
No significant changeAdhesions
Study
n: not reported in source
Outcome group
Organ injury · Reproductive and sexual health
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
No effect was seen on adhesions.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized and double-blind trial was carried out comparing intranasal nafarelin acetate (400 micrograms daily) and oral danazol (600 mg daily), given over 6 months, in the treatment of 49 patients with laparoscopically proven endometriosis.
Report a problemFND-0183404903
09HumanNon-randomized trialMechanism
In patients with endometriosis, nafarelin caused a substantial oestradiol rise during the first 2 weeks of therapy.
In plain wordsIn patients with endometriosis, oestradiol rose during the first 2 weeks of nafarelin therapy.
Peptide
Nafarelin
Outcome
IncreaseInitial oestradiol rise
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
400 micrograms daily · intranasalAs given in this study (human).
Source sentences
Summary
Both drugs suppressed oestradiol levels to a similar extent, although nafarelin caused a substantial rise in the first 2 weeks after the initiation of therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized and double-blind trial was carried out comparing intranasal nafarelin acetate (400 micrograms daily) and oral danazol (600 mg daily), given over 6 months, in the treatment of 49 patients with laparoscopically proven endometriosis.
Report a problemFND-0183404905
10HumanNon-randomized trialMechanism
In patients with endometriosis, nafarelin substantially suppressed LH.
In plain wordsIn patients with endometriosis, nafarelin substantially reduced LH.
Peptide
Nafarelin
Outcome
DecreaseLH
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Nafarelin suppressed LH substantially and FSH, testosterone and prolactin to a small degree, whereas FSH and LH increased slightly during danazol.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized and double-blind trial was carried out comparing intranasal nafarelin acetate (400 micrograms daily) and oral danazol (600 mg daily), given over 6 months, in the treatment of 49 patients with laparoscopically proven endometriosis.
Report a problemFND-0183404906
11HumanNon-randomized trialMechanism
In patients with endometriosis, nafarelin suppressed FSH to a small degree.
In plain wordsIn patients with endometriosis, nafarelin slightly reduced FSH.
Peptide
Nafarelin
Outcome
DecreaseFSH
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Nafarelin suppressed LH substantially and FSH, testosterone and prolactin to a small degree, whereas FSH and LH increased slightly during danazol.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized and double-blind trial was carried out comparing intranasal nafarelin acetate (400 micrograms daily) and oral danazol (600 mg daily), given over 6 months, in the treatment of 49 patients with laparoscopically proven endometriosis.
Report a problemFND-0183404907
12HumanNon-randomized trialMechanism
In patients with endometriosis, nafarelin suppressed testosterone to a small degree.
In plain wordsIn patients with endometriosis, nafarelin slightly reduced testosterone.
Peptide
Nafarelin
Outcome
DecreaseTestosterone
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Nafarelin suppressed LH substantially and FSH, testosterone and prolactin to a small degree, whereas FSH and LH increased slightly during danazol.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized and double-blind trial was carried out comparing intranasal nafarelin acetate (400 micrograms daily) and oral danazol (600 mg daily), given over 6 months, in the treatment of 49 patients with laparoscopically proven endometriosis.
Report a problemFND-0183404908
13HumanNon-randomized trialMechanism
In patients with endometriosis, nafarelin suppressed prolactin to a small degree.
In plain wordsIn patients with endometriosis, nafarelin slightly reduced prolactin.
Peptide
Nafarelin
Outcome
DecreaseProlactin
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Nafarelin suppressed LH substantially and FSH, testosterone and prolactin to a small degree, whereas FSH and LH increased slightly during danazol.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized and double-blind trial was carried out comparing intranasal nafarelin acetate (400 micrograms daily) and oral danazol (600 mg daily), given over 6 months, in the treatment of 49 patients with laparoscopically proven endometriosis.
Report a problemFND-0183404909
14HumanNon-randomized trialSafety outcome
In patients with endometriosis, hot flushes were the predominant nafarelin side effect.
In plain wordsIn patients with endometriosis, hot flushes were the main nafarelin side effect.
Peptide
Nafarelin
Outcome
Not applicableHot flushes
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Hot flushes were the predominant side effect with nafarelin, although oestradiol levels were not suppressed to the extent expected.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized and double-blind trial was carried out comparing intranasal nafarelin acetate (400 micrograms daily) and oral danazol (600 mg daily), given over 6 months, in the treatment of 49 patients with laparoscopically proven endometriosis.
Report a problemFND-0183404912
15HumanNon-randomized trialSafety outcome
In patients with endometriosis, spotting or light bleeding occurred with nafarelin and tended to decrease over time.
In plain wordsIn patients with endometriosis, spotting or light bleeding tended to decrease during nafarelin therapy.
Peptide
Nafarelin
Outcome
DecreaseSpotting or light bleeding
Study
n: not reported in source
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Small amounts of spotting or light bleeding were experienced with both drugs, but these tended to decrease with time with nafarelin and increase with danazol.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized and double-blind trial was carried out comparing intranasal nafarelin acetate (400 micrograms daily) and oral danazol (600 mg daily), given over 6 months, in the treatment of 49 patients with laparoscopically proven endometriosis.
Report a problemFND-0183404913

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.